BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Philip Morris International Inc. (“Philip Morris” or the “Company”) (NYSE: PM) investors concerning the Company and its officers’ possible violations of federal securities laws.
On December 20, 2017, Reuters reported that former Phillip Morris employees and contractors “detailed irregularities in the clinical experiments that underpin Philip Morris International's application to the FDA for approval of its iQOS smoking device.” The report further stated that Tamara Koval, who helped coordinate clinical trials for the device, was “excluded from meetings” after she “questioned the quality of some of the researchers and sites contracted to carry out those experiments.”
On this news, shares of Philip Morris fell $3.75, or nearly 3.5%, to close at $104.37 on December 20, 2017, thereby injuring investors.
If you purchased Philip Morris securities, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.